Sumitomo Offers to Buy All of Myovant in $2.5 Billion Deal

Published on 3 Oct 2022 on Bloomberg via Yahoo Finance

Sumitomo Offers to Buy All of Myovant in $2.5 Billion Deal

(Bloomberg) -- A fully-owned subsidiary of Sumitomo Pharma Co. offered to buy the remaining outstanding shares of pharmaceutical company Myovant Sciences Ltd., seeking to bolster the development of drugs for women’s health and prostate cancer.

Want to become a better investor?

Start tracking your investments with Statfolio

Asia Deal Digest: Sullivan & Cromwell, Skadden, Latham, Allen & Gledhill Gain With Billion-Dollar...

These deals were spread across Asia, taking place in Japan, Singapore, Mainland China, Taiwan,...

Law.com 4 Nov 2022

Deal Watch: Twitter Deal Is Done, but the Legal Work Likely Isn't | The American Lawyer

While Elon Musk closed the $44 billion Twitter deal, the work from lawyers may be far from over....

Law.com 31 Oct 2022

Myovant Sciences shares trading higher after agreeing to Sumitomo deal for $2.9 billion

Shares of Myovant Sciences Ltd. were up 8.2% in premarket trading on Monday, the day after the co...

MarketWatch 28 Oct 2022

Myovant Sciences: Fiscal Q2 Earnings Snapshot

LONDON (AP) _ Myovant Sciences Ltd. (MYOV) on Wednesday reported a loss of $45.6 million...

Stamford Advocate 26 Oct 2022

Peninsula drug company Myovant to go private in $1.7 billion buyout

A company led by former Genentech Inc. president Myrtle Potter will buy part of Brisbane-based dr...

American City Business Journals 24 Oct 2022

Drug maker Myovant to go private in $1.7 billion deal driven by Sumitomo Pharma - San Francisco...

Myovant's board had rejected an earlier bid, but a sweetened offer drew a different response.

The Business Journals 24 Oct 2022

Sumitomo Unit Agrees to Buy Myovant After Increasing Offer

(Bloomberg) -- A fully-owned subsidiary of Sumitomo Pharma Co. agreed to buy the rest of drugmake...

Bloomberg via Yahoo Finance 24 Oct 2022

Myovant Sciences shares trading higher after agreeing to Sumitomo deal for $2.9 billion

Shares of Myovant Sciences Ltd. were up 8.2% in premarket trading on Monday, the day after the co...

Market Watch 24 Oct 2022

Myovant Sciences: What The Sumitomo Offer Foretells (NYSE:MYOV)

One of the most exciting times in biotech investing is when a company received an offer from a...

Seeking Alpha 7 Oct 2022

Sumitomo Offers to Buy All of Myovant in $2.5 Billion Deal

(Bloomberg) -- A fully-owned subsidiary of Sumitomo Pharma Co. offered to buy the remaining outst...

Bloomberg via Yahoo Finance 3 Oct 2022

News

Sumitomo Offers to Buy All of Myovant in $2.5 Billion Deal

Want to become a better investor?